AbbVie (ABBV)
(Delayed Data from NYSE)
$189.29 USD
-0.42 (-0.22%)
Updated Aug 2, 2024 04:00 PM ET
After-Market: $189.00 -0.29 (-0.15%) 7:02 PM ET
3-Hold of 5 3
C Value C Growth F Momentum C VGM
Price, Consensus and EPS Surprise
ABBV 189.29 -0.42(-0.22%)
Will ABBV be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ABBV based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ABBV
Should You Buy AbbVie (ABBV) After Q2 Beat, Guidance Raise?
TEVA Q2 Earnings Beat, Generic Business Drives Sales, Stock Up
ABBV: What are Zacks experts saying now?
Zacks Private Portfolio Services
Investors Heavily Search AbbVie Inc. (ABBV): Here is What You Need to Know
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises
Other News for ABBV
See Which Of The Latest 13F Filers Holds AbbVie
Neurocrine Biosciences Delivering Strong Core Results, And Significant Pipeline Value Could Be On The Way
Here's How Much You Would Have Made Owning AbbVie Stock In The Last 10 Years
8 Health Care Stocks With Whale Alerts In Today's Session
AbbVie completes acquisition of Cerevel Therapeutics